Clinical trials referenced in this document:
Documents that mention this clinical trial
Evaluation of Proenkephalin A 119–159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (ZA428/18-1, ZA428/10-1)
Received: 14 February 2023
Accepted: 28 June 2023
First Online: 10 July 2023
: Institutional review board approval was obtained from the Research Ethics Committee of the Chamber of Physicians Westfalen–Lippe and the University of Münster and the corresponding institutional review boards of all participating centers. The trial was approved by the Federal Institute for Drugs and Medical Devices in Germany.
: All authors read and approved the final manuscript for publication.
: Birte Arlt is employed at SphingoTec GmbH, the company that holds patent rights related to the sphingotest<sup>®</sup> penKid<sup>®</sup> assay. Peter Pickkers has received consultancy and travel reimbursements from SphingoTec. The other authors declare no competing interests in relation to the study.